The Food and Drug Administration March 14 released a notice on a nationwide shortage of hemodialysis tubes expected to last through early fall. On Jan. 8, B. Braun sent a letter to customers detailing an interruption to the production and supply of certain hemodialysis tubes.  
 
The FDA recommended providers experiencing interruptions or shortages to “use their clinical judgment when developing and implementing conservation strategies.” The FDA said providers should continue providing dialysis treatments to patients, monitor current and future tube supplies, and develop plans and strategies to conserve tube supply, among other recommendations. 

Related News Articles

Headline
The AHA submitted a statement today to the House Energy and Commerce Subcommittee on Health for a hearing today on the health care supply chain. The AHA…
Headline
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response June 5 announced it selected two locations to test an…
Headline
The U.S. Court of International Trade May 28 blocked a series of tariffs issued by the Trump administration under the International Emergency Economic Powers…
Chairperson's File
Public
We are all closely watching changing tariff policy as it raises serious considerations for the medical products, devices and pharmaceuticals supply chain. Our…
Chairperson's File
Public
Most hospitals and health systems are the largest organizations in our communities, providing critical services needed by every one of our neighbors. We take…
Headline
The AHA May 16 urged the Department of Commerce to consider tariff exceptions for critical minerals and derivative products used for medical purposes. Critical…